TY - JOUR
T1 - Hematopoietic Stem Cell Transplantation in an International Cohort of Colony Stimulating Factor-1 Receptor (CSF1R)-Related Disorder
AU - and the International CSF1R-RD Working Group
AU - Yska, Hemmo A.F.
AU - Golse, Marianne
AU - Beerepoot, Shanice
AU - Hayer, Stefanie
AU - Bergner, Caroline
AU - de Paiva, Anderson Rodrigues Brandao
AU - Marelli, Cecilia
AU - Palacios, Natalia Julia
AU - Osorio, Yudy Llamas
AU - Huiban, Camille
AU - Franke, Georg
AU - Wortmann, Friederike
AU - Holtick, Udo
AU - Ayrignac, Xavier
AU - van der Knaap, Marjo S.
AU - Schöls, Ludger
AU - Perlbarg, Vincent
AU - Galanaud, Damien
AU - de Witte, Moniek A.
AU - Wolf, Nicole I.
AU - Nguyen, Stéphanie
AU - Mochel, Fanny
AU - Köhler, Wolfgang
AU - Garcia-Cazorla, Angeles
AU - Souchet, Laetitia
AU - Chaumette, Boris
AU - Blanco, Bernardo
AU - Barbier, Magali
AU - Stankoff, Bruno
AU - Dubessy, Anne Laure
AU - Robert-Varvat, Florence
AU - Riou, Audrey
AU - Weber, Sacha
AU - Bender, Benjamin
AU - Fegueux, Nathalie
AU - Ceballos, Patrice
AU - de Champfleur, Nicolas Menjot
AU - Lehmann, Sylvain
AU - Cara-Dallière, Clarisse
AU - Labauge, Pierre
AU - Lindemans, Caroline
AU - Freua, Fernando
AU - Mariano, Livia
AU - Lucato, Leandro Tavares
AU - Fernandes, Gustavo Bruniera Peres
AU - de Gusmão, Claudio M.
AU - Filho, José Ulysses Amigo
AU - Kok, Fernando
AU - Turon, Laia
AU - Badell, Isabel
N1 - © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
PY - 2025/9
Y1 - 2025/9
N2 - Background: Colony stimulating factor-1 receptor (CSF1R)-related disorder (CSF1R-RD) is an autosomal dominant, rapidly progressive, demyelinating disease leading to death usually within a few years. Because of the central role of CSF1R in microglia functions, allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested as a therapy for CSF1R-RD. Objectives: To report multicenter clinical (Expanded Disability Scoring Scale [EDSS]), neurocognitive), neuroimaging (Sundal score), and biological (neurofilament light chain [NfL]) outcomes after HSCT in CSF1R-RD. Methods: We report an international cohort of 17 adult patients (8 females/9 males, 43.3 ± 9.4 years) who were treated in seven transplant centers. Patients were evaluated for a median of 2.5 years post-HSCT, including one patient with follow-up of 8 years. We also report neurological outcomes of the first child transplanted to date with biallelic CSF1R variants. Results: In the first 6 months post-HSCT, 2 patients died from early complications of myeloablative transplantation, and clinical and radiological severity scores worsened in most surviving adult patients. At 12 months post-HSCT, most patients completely stabilized or improved in certain clinical domains. Radiological scores fully stabilized or slightly improved in all but one of the patients. Plasma/serum NfL sharply decreased in most patients after transplantation. Notably, 7/8 adult patients who received a reduced-intensity conditioning regimen displayed similar neurological outcomes as patients who underwent myeloablative transplantation. Conclusions: After an initial clinical and radiological deterioration in the first 6 months post-transplantation, HSCT can halt disease progression in patients with CSF1R-RD, regardless of their presenting clinical symptoms. The possibility of reduced conditioning regimens in CSF1R-RD opens the way to treat older patients.
AB - Background: Colony stimulating factor-1 receptor (CSF1R)-related disorder (CSF1R-RD) is an autosomal dominant, rapidly progressive, demyelinating disease leading to death usually within a few years. Because of the central role of CSF1R in microglia functions, allogeneic hematopoietic stem cell transplantation (HSCT) has been suggested as a therapy for CSF1R-RD. Objectives: To report multicenter clinical (Expanded Disability Scoring Scale [EDSS]), neurocognitive), neuroimaging (Sundal score), and biological (neurofilament light chain [NfL]) outcomes after HSCT in CSF1R-RD. Methods: We report an international cohort of 17 adult patients (8 females/9 males, 43.3 ± 9.4 years) who were treated in seven transplant centers. Patients were evaluated for a median of 2.5 years post-HSCT, including one patient with follow-up of 8 years. We also report neurological outcomes of the first child transplanted to date with biallelic CSF1R variants. Results: In the first 6 months post-HSCT, 2 patients died from early complications of myeloablative transplantation, and clinical and radiological severity scores worsened in most surviving adult patients. At 12 months post-HSCT, most patients completely stabilized or improved in certain clinical domains. Radiological scores fully stabilized or slightly improved in all but one of the patients. Plasma/serum NfL sharply decreased in most patients after transplantation. Notably, 7/8 adult patients who received a reduced-intensity conditioning regimen displayed similar neurological outcomes as patients who underwent myeloablative transplantation. Conclusions: After an initial clinical and radiological deterioration in the first 6 months post-transplantation, HSCT can halt disease progression in patients with CSF1R-RD, regardless of their presenting clinical symptoms. The possibility of reduced conditioning regimens in CSF1R-RD opens the way to treat older patients.
KW - CSF1R-RD
KW - adult-onset leukoencephalopathy with axonal spheroids and pigmented glia
KW - demyelination
KW - hematopoietic stem cell transplantation
KW - neurofilament light chain
KW - neuroinflammation
KW - Humans
KW - Middle Aged
KW - Male
KW - Receptor, Macrophage Colony-Stimulating Factor
KW - Treatment Outcome
KW - Hematopoietic Stem Cell Transplantation/methods
KW - Adult
KW - Female
KW - Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/genetics
KW - Cohort Studies
UR - https://www.scopus.com/pages/publications/105013764187
UR - https://www.mendeley.com/catalogue/2ac6950b-5c9c-3953-a08d-56a7fad792e9/
U2 - 10.1002/mds.30282
DO - 10.1002/mds.30282
M3 - Article
C2 - 40646711
AN - SCOPUS:105013764187
SN - 0885-3185
VL - 40
SP - 1826
EP - 1835
JO - Movement Disorders
JF - Movement Disorders
IS - 9
ER -